Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 32, Issue 23, Pages 2423-2429
Publisher
American Society of Clinical Oncology (ASCO)
Online
2014-07-01
DOI
10.1200/jco.2013.53.6995
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Weekly Docetaxel as Salvage Therapy in Patients with Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2014) S. Cereda et al. JOURNAL OF CHEMOTHERAPY
- Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials
- (2013) O. E. Rahma et al. ANNALS OF ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
- (2011) Uwe Pelzer et al. EUROPEAN JOURNAL OF CANCER
- A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer
- (2011) Daniel J. Renouf et al. INVESTIGATIONAL NEW DRUGS
- A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
- (2011) György Bodoky et al. INVESTIGATIONAL NEW DRUGS
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oxaliplatin, 5-Fluorouracil, and Leucovorin as Second-Line Treatment for Advanced Pancreatic Cancer
- (2010) Anna Novarino et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma
- (2010) Igor A. Astsaturov et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- S-1 Monotherapy as Second-line Treatment for Advanced Pancreatic Cancer after Gemcitabine Failure
- (2010) A. Todaka et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603)
- (2010) E. M. O'Reilly et al. ONCOLOGIST
- A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
- (2009) C Yoo et al. BRITISH JOURNAL OF CANCER
- Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer
- (2008) Henry Q. Xiong et al. CANCER
- Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
- (2008) Seong Yoon Yi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer
- (2008) Brian M. Wolpin et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search